Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Guide for considering influenza testing when influenza viruses are circulating in the community

Figure: Guide for considering influenza testing when influenza viruses are circulating in the community (regardless of influenza vaccination history)1

	Figure: Guide for considering influenza testing when influenza viruses are circulating in the community(regardless of influenza vaccination history)

1. Confirmation of influenza virus infection by diagnostic testing is not required for decisions to prescribe antiviral medication. Decision-making should be based upon signs and symptoms consistent with influenza illness and epidemiologic factors. Initiation of empiric antiviral treatment should not be delayed while influenza testing results are pending. Antiviral treatment is clinically most beneficial when started as close to illness onset as possible. Influenza vaccine effectiveness  is moderate and  so a history of current season influenza vaccination does not exclude a diagnosis of influenza.

2. Signs and symptoms of uncomplicated influenza vary by age, underlying health conditions, and immune function. Common signs and symptoms include fever with nonproductive cough or other suggestive respiratory symptoms, often with myalgias or headache. Fever is not always present, including in premature and young infants, immunocompromised and immunosuppressed persons, and especially in elderly persons. Note that some persons may have atypical presentations -especially infants (e.g. sepsis-like syndrome) and elderly (e.g. confusion).

3. Complications associated with influenza can vary by age, immune status, and underlying medical conditions. Some examples include worsening of underlying chronic medical conditions (e.g. worsening of congestive cardiac failure; asthma exacerbation; exacerbation of chronic obstructive pulmonary disease); lower respiratory tract disease (pneumonia, bronchiolitis, croup, respiratory failure); invasive bacterial co-infection; cardiac (e.g.myocarditis); musculoskeletal (e.g. myositis, rhabdomyolysis); neurologic (e.g. encephalopathy, encephalitis); multi-organ failure (septic shock, renal failure, respiratory failure).

4. Influenza testing may be used to inform decisions on use of antiviral treatment, antibiotic treatment, need for further diagnostic tests, consideration for home care, or on recommendations for ill persons living with others who are at high-risk for influenza complications. Proper interpretation of influenza testing results must consider a number of factors, including: the predictive values of the test, test sensitivity and specificity compared to a “gold standard” test, prevalence of influenza in the patient population, time from illness onset to specimen collection and whether the person may still have detectable influenza viral shedding, and source of the respiratory specimen (upper or lower respiratory tract). To maximize detection of influenza viruses, respiratory specimens should be collected as close to illness onset as possible (ideally <3-4 days after onset; molecular assays may detect influenza viral RNA in respiratory tract specimens for longer periods after illness onset than antigen detection assays). See this algorithm for more information. Consult guidance on antibiotic use from the IDSA, ATS, and the AAP. Antiviral treatment is recommended as soon as possible for hospitalized patients with suspected influenza without waiting for influenza testing results of molecular assays. See Antiviral Drugs: Information for Health Care Professionals for more information.

5. All hospitalized patients with suspected influenza should be tested with molecular assays with high sensitivity and specificity (e.g. RT-PCR) since detection of influenza virus infection and prompt initiation of antiviral therapy is most clinically beneficial, and prompt  implementation of infection prevention and control measures is essential for prevention of nosocomial influenza outbreaks. Molecular assays can detect influenza viral RNA in respiratory specimens for longer periods than antigen detection assays. For hospitalized patients with lower respiratory tract disease and suspected influenza, lower respiratory tract specimens should be collected and tested for influenza viruses by RT-PCR because influenza viral shedding in the lower respiratory tract may be detectable for longer periods than in the upper respiratory tract, if influenza testing of upper respiratory tract specimens yields a negative result. If the patient is critically ill on invasive mechanical ventilation, and has tested negative on an upper respiratory tract specimen, including by a molecular assay, a lower respiratory tract specimen (endotracheal aspirate or bronchioalveolar lavage fluid) should be collected for influenza testing by RT-PCR or other molecular assays. See Prevention Strategies for Seasonal Influenza in Health Care Settings for more information.

6. Influenza testing may help  inform decisions on infection prevention and control practices. See Prevention Strategies for Seasonal Influenza in Health Care Settings for more information.

7. Persons who are at Higher Risk of Complications from Influenza include those aged ≥65 years or <2 years; pregnant women; persons with chronic lung disease (including asthma), heart disease, renal, metabolic, hematologic and neurologic disease; immunosuppression; and morbid obesity; American Indians or Alaska Natives, and residents of chronic care facilities.

8. Antiviral treatment is recommended as soon as possible for outpatients with suspected or confirmed influenza who are at high-risk for complications from influenza, or those with progressive disease not requiring hospital admission. Outpatients who are not at higher risk of complications from influenza can be considered based upon clinical judgement if presenting within 2 days of illness onset.

Top